A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells

Jlenia Guarnerio, Luisa Riccardi, Riccardo Taulli, Takahiro Maeda, Guocan Wang, Robin M. Hobbs, Min Sup Song, Paolo Sportoletti, Rosa Bernardi, Roderick T. Bronson, Mireia Castillo-Martin, Carlos Cordon-Cardo, Andrea Lunardi, Pier Paolo Pandolfi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The regulatory factors governing adult mesenchymal stem cell (MSC) physiology and their tumorigenic potential are still largely unknown, which substantially delays the identification of effective therapeutic approaches for the treatment of aggressive and lethal forms of MSC-derived mesenchymal tumors, such as undifferentiated sarcomas. Here, we have developed a novel platform to screen and quickly identify genes and pathways responsible for adult MSC transformation, modeled undifferentiated sarcoma in vivo , and, ultimately, tested the efficacy of targeting the identified oncopathways. Importantly, by taking advantage of this new platform, we demonstrate the key role of an aberrant LRF–DLK1–SOX9 pathway in the pathogenesis of undifferentiated sarcoma, with important therapeutic implications. SIGNIFICANCE: The paucity of therapeutic options for the treatment of sarcoma calls for a rapid and effective preclinical assessment of new therapeutic modalities. We have here developed a new platform to deconstruct the molecular genetics underlying the pathogenesis of sarcoma and to evaluate in vivo the efficacy of novel targeted therapies.

Original languageEnglish
Pages (from-to)396-409
Number of pages14
JournalCancer Discovery
Volume5
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Adult Stem Cells
Mesenchymal Stromal Cells
Sarcoma
Therapeutics
Cell Physiological Phenomena
Molecular Biology
Genes
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Guarnerio, J., Riccardi, L., Taulli, R., Maeda, T., Wang, G., Hobbs, R. M., ... Pandolfi, P. P. (2015). A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. Cancer Discovery, 5(4), 396-409. https://doi.org/10.1158/2159-8290.CD-14-1022

A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. / Guarnerio, Jlenia; Riccardi, Luisa; Taulli, Riccardo; Maeda, Takahiro; Wang, Guocan; Hobbs, Robin M.; Song, Min Sup; Sportoletti, Paolo; Bernardi, Rosa; Bronson, Roderick T.; Castillo-Martin, Mireia; Cordon-Cardo, Carlos; Lunardi, Andrea; Pandolfi, Pier Paolo.

In: Cancer Discovery, Vol. 5, No. 4, 01.04.2015, p. 396-409.

Research output: Contribution to journalArticle

Guarnerio, J, Riccardi, L, Taulli, R, Maeda, T, Wang, G, Hobbs, RM, Song, MS, Sportoletti, P, Bernardi, R, Bronson, RT, Castillo-Martin, M, Cordon-Cardo, C, Lunardi, A & Pandolfi, PP 2015, 'A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells', Cancer Discovery, vol. 5, no. 4, pp. 396-409. https://doi.org/10.1158/2159-8290.CD-14-1022
Guarnerio, Jlenia ; Riccardi, Luisa ; Taulli, Riccardo ; Maeda, Takahiro ; Wang, Guocan ; Hobbs, Robin M. ; Song, Min Sup ; Sportoletti, Paolo ; Bernardi, Rosa ; Bronson, Roderick T. ; Castillo-Martin, Mireia ; Cordon-Cardo, Carlos ; Lunardi, Andrea ; Pandolfi, Pier Paolo. / A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells. In: Cancer Discovery. 2015 ; Vol. 5, No. 4. pp. 396-409.
@article{e33446719a97498d9c254c0c952e963a,
title = "A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells",
abstract = "The regulatory factors governing adult mesenchymal stem cell (MSC) physiology and their tumorigenic potential are still largely unknown, which substantially delays the identification of effective therapeutic approaches for the treatment of aggressive and lethal forms of MSC-derived mesenchymal tumors, such as undifferentiated sarcomas. Here, we have developed a novel platform to screen and quickly identify genes and pathways responsible for adult MSC transformation, modeled undifferentiated sarcoma in vivo , and, ultimately, tested the efficacy of targeting the identified oncopathways. Importantly, by taking advantage of this new platform, we demonstrate the key role of an aberrant LRF–DLK1–SOX9 pathway in the pathogenesis of undifferentiated sarcoma, with important therapeutic implications. SIGNIFICANCE: The paucity of therapeutic options for the treatment of sarcoma calls for a rapid and effective preclinical assessment of new therapeutic modalities. We have here developed a new platform to deconstruct the molecular genetics underlying the pathogenesis of sarcoma and to evaluate in vivo the efficacy of novel targeted therapies.",
author = "Jlenia Guarnerio and Luisa Riccardi and Riccardo Taulli and Takahiro Maeda and Guocan Wang and Hobbs, {Robin M.} and Song, {Min Sup} and Paolo Sportoletti and Rosa Bernardi and Bronson, {Roderick T.} and Mireia Castillo-Martin and Carlos Cordon-Cardo and Andrea Lunardi and Pandolfi, {Pier Paolo}",
year = "2015",
month = "4",
day = "1",
doi = "10.1158/2159-8290.CD-14-1022",
language = "English",
volume = "5",
pages = "396--409",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells

AU - Guarnerio, Jlenia

AU - Riccardi, Luisa

AU - Taulli, Riccardo

AU - Maeda, Takahiro

AU - Wang, Guocan

AU - Hobbs, Robin M.

AU - Song, Min Sup

AU - Sportoletti, Paolo

AU - Bernardi, Rosa

AU - Bronson, Roderick T.

AU - Castillo-Martin, Mireia

AU - Cordon-Cardo, Carlos

AU - Lunardi, Andrea

AU - Pandolfi, Pier Paolo

PY - 2015/4/1

Y1 - 2015/4/1

N2 - The regulatory factors governing adult mesenchymal stem cell (MSC) physiology and their tumorigenic potential are still largely unknown, which substantially delays the identification of effective therapeutic approaches for the treatment of aggressive and lethal forms of MSC-derived mesenchymal tumors, such as undifferentiated sarcomas. Here, we have developed a novel platform to screen and quickly identify genes and pathways responsible for adult MSC transformation, modeled undifferentiated sarcoma in vivo , and, ultimately, tested the efficacy of targeting the identified oncopathways. Importantly, by taking advantage of this new platform, we demonstrate the key role of an aberrant LRF–DLK1–SOX9 pathway in the pathogenesis of undifferentiated sarcoma, with important therapeutic implications. SIGNIFICANCE: The paucity of therapeutic options for the treatment of sarcoma calls for a rapid and effective preclinical assessment of new therapeutic modalities. We have here developed a new platform to deconstruct the molecular genetics underlying the pathogenesis of sarcoma and to evaluate in vivo the efficacy of novel targeted therapies.

AB - The regulatory factors governing adult mesenchymal stem cell (MSC) physiology and their tumorigenic potential are still largely unknown, which substantially delays the identification of effective therapeutic approaches for the treatment of aggressive and lethal forms of MSC-derived mesenchymal tumors, such as undifferentiated sarcomas. Here, we have developed a novel platform to screen and quickly identify genes and pathways responsible for adult MSC transformation, modeled undifferentiated sarcoma in vivo , and, ultimately, tested the efficacy of targeting the identified oncopathways. Importantly, by taking advantage of this new platform, we demonstrate the key role of an aberrant LRF–DLK1–SOX9 pathway in the pathogenesis of undifferentiated sarcoma, with important therapeutic implications. SIGNIFICANCE: The paucity of therapeutic options for the treatment of sarcoma calls for a rapid and effective preclinical assessment of new therapeutic modalities. We have here developed a new platform to deconstruct the molecular genetics underlying the pathogenesis of sarcoma and to evaluate in vivo the efficacy of novel targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=84939502453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939502453&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-14-1022

DO - 10.1158/2159-8290.CD-14-1022

M3 - Article

C2 - 25614485

AN - SCOPUS:84939502453

VL - 5

SP - 396

EP - 409

JO - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 4

ER -